• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Infliximab treatment for rheumatic disease: clinical and radiological efficacy.英夫利昔单抗治疗风湿性疾病：临床及影像学疗效
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii67-9. doi: 10.1136/ard.61.suppl_2.ii67.
2
The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.抗肿瘤坏死因子α药物在类风湿关节炎、银屑病关节炎和强直性脊柱炎患者中的一年疗效比较：一项纵向、观察性、多中心研究的结果
Arthritis Rheum. 2008 Feb 15;59(2):234-40. doi: 10.1002/art.23333.
3
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.在患有风湿性疾病的HIV阳性个体中使用抗肿瘤坏死因子疗法。
Ann Rheum Dis. 2008 May;67(5):710-2. doi: 10.1136/ard.2007.081513. Epub 2007 Dec 13.
4
[Autoimmune aspects of treatment with TNF-alpha inhibitors].[肿瘤坏死因子-α抑制剂治疗的自身免疫相关问题]
Postepy Hig Med Dosw (Online). 2007 Aug 28;61:478-84.
5
Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients.类风湿关节炎患者接受英夫利昔单抗治疗后并发结核感染：157 例患者的经验。
Rheumatol Int. 2012 Sep;32(9):2769-75. doi: 10.1007/s00296-011-2017-5. Epub 2011 Aug 7.
6
Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.炎症性肠病在治疗炎症性风湿性疾病的抗 TNF-α 治疗期间的发展：全国系列研究。
Joint Bone Spine. 2012 Oct;79(5):457-63. doi: 10.1016/j.jbspin.2011.10.001. Epub 2011 Nov 15.
7
[Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].[抗TNFα在类风湿关节炎和强直性脊柱炎治疗中的应用]
Presse Med. 2009 May;38(5):774-87. doi: 10.1016/j.lpm.2009.02.003. Epub 2009 Mar 26.
8
The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.泰国人群中抗肿瘤坏死因子药物的感染谱：一项基于大学医院的回顾性研究。
Int J Rheum Dis. 2009 Jul;12(2):118-24. doi: 10.1111/j.1756-185X.2009.01393.x.
9
[Biologicals in the treatment of rheumatic diseases].[生物制剂在风湿性疾病治疗中的应用]
Dtsch Med Wochenschr. 2006 Oct 13;131(41):2279-85. doi: 10.1055/s-2006-951364.
10
Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).肿瘤坏死因子作为类风湿关节炎及其他慢性炎症性疾病的治疗靶点：英夫利昔单抗（类克）的临床经验
Int J Clin Pract. 2001 Apr;55(3):211-6.

引用本文的文献

1
Tumor Necrosis Factor-Alpha Antagonist Interferes With the Formation of Granulomatous Multinucleated Giant Cells: New Insights Into Infection.肿瘤坏死因子-α拮抗剂干扰多核巨细胞肉芽肿的形成：对 感染的新认识。
Front Immunol. 2019 Aug 14;10:1947. doi: 10.3389/fimmu.2019.01947. eCollection 2019.
2
Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients.类风湿关节炎患者持续临床缓解时，身体功能会持续改善。
Arthritis Res Ther. 2015 Aug 11;17(1):203. doi: 10.1186/s13075-015-0719-x.
3
[Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy].[银屑病关节炎——对风湿病学家和患者的长期挑战：第2部分：影像学诊断、分类与治疗]
Z Rheumatol. 2011 Nov;70(9):775-89. doi: 10.1007/s00393-011-0870-y.
4
Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography.依那西普治疗类风湿关节炎：一年超声临床随访
Clin Rheumatol. 2008 Apr;27(4):491-6. doi: 10.1007/s10067-007-0738-3. Epub 2007 Oct 19.
5
Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.组蛋白去乙酰化酶（HDAC）抑制剂在啮齿动物胶原诱导性关节炎体内的抗风湿活性。
Br J Pharmacol. 2007 Apr;150(7):862-72. doi: 10.1038/sj.bjp.0707165. Epub 2007 Feb 26.
6
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.阿达木单抗的临床疗效与类风湿因子及抗环瓜氨酸肽抗体滴度降低相关：一项为期一年的前瞻性研究。
Arthritis Res Ther. 2006;8(1):R3. doi: 10.1186/ar1851.
7
Rheumatoid arthritis as a hyper-endoplasmic-reticulum-associated degradation disease.类风湿关节炎作为一种内质网应激相关降解疾病。
Arthritis Res Ther. 2005;7(5):181-6. doi: 10.1186/ar1808. Epub 2005 Aug 17.
8
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.类风湿关节炎患者接受抗TNFα治疗（英夫利昔单抗）后，抗环瓜氨酸肽抗体和类风湿因子水平降低与临床症状改善相关。
Ann Rheum Dis. 2004 Oct;63(10):1218-21. doi: 10.1136/ard.2003.014647.
9
Biologic agents for the treatment of juvenile rheumatoid arthritis: current status.用于治疗青少年类风湿性关节炎的生物制剂：现状
Paediatr Drugs. 2004;6(3):137-46. doi: 10.2165/00148581-200406030-00001.
10
Blocking lymphotoxin-beta receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis.在慢性右旋糖酐硫酸钠（DSS）诱导的结肠炎中，阻断淋巴毒素-β受体激活可通过降低黏膜地址素细胞黏附分子-1（MAdCAM-1）的表达和白细胞边缘化来减轻炎症。
Clin Exp Immunol. 2004 Apr;136(1):21-9. doi: 10.1111/j.1365-2249.2004.02402.x.

本文引用的文献

1
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.血清英夫利昔单抗浓度与类风湿关节炎临床改善的关系：多中心、随机、双盲、安慰剂对照试验ATTRACT的结果
Arthritis Rheum. 2002 Jun;46(6):1451-9. doi: 10.1002/art.10302.
2
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.英夫利昔单抗治疗活动性强直性脊柱炎：一项随机对照多中心试验。
Lancet. 2002 Apr 6;359(9313):1187-93. doi: 10.1016/s0140-6736(02)08215-6.
3
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.嵌合型肿瘤坏死因子α单克隆抗体（英夫利昔单抗）与安慰剂在活动性脊柱关节病中的随机双盲对照研究
Arthritis Rheum. 2002 Mar;46(3):755-65. doi: 10.1002/art.511.
4
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.对活动性脊柱关节病患者重复输注英夫利昔单抗（一种嵌合抗TNFα单克隆抗体）：一年随访
Ann Rheum Dis. 2002 Mar;61(3):207-12. doi: 10.1136/ard.61.3.207.
5
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.英夫利昔单抗单药治疗斑块型银屑病的疗效和安全性：一项随机试验。
Lancet. 2001 Jun 9;357(9271):1842-7. doi: 10.1016/s0140-6736(00)04954-0.
6
Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.使用抗肿瘤坏死因子-α抗体治疗银屑病关节炎可清除对甲氨蝶呤治疗耐药的银屑病皮肤病变。
Br J Dermatol. 2001 Mar;144(3):587-9. doi: 10.1046/j.1365-2133.2001.04089.x.
7
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.英夫利昔单抗与甲氨蝶呤治疗类风湿关节炎。类风湿关节炎联合治疗抗肿瘤坏死因子试验研究组。
N Engl J Med. 2000 Nov 30;343(22):1594-602. doi: 10.1056/NEJM200011303432202.
8
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.依那西普治疗银屑病关节炎和银屑病：一项随机试验。
Lancet. 2000 Jul 29;356(9227):385-90. doi: 10.1016/S0140-6736(00)02530-7.
9
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.使用抗肿瘤坏死因子α单克隆抗体英夫利昔单抗成功治疗活动性强直性脊柱炎。
Arthritis Rheum. 2000 Jun;43(6):1346-52. doi: 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E.
10
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.三次输注肿瘤坏死因子α嵌合单克隆抗体（英夫利昔单抗）负荷剂量方案对脊柱关节病的影响：一项开放性初步研究。
Ann Rheum Dis. 2000 Jun;59(6):428-33. doi: 10.1136/ard.59.6.428.

英夫利昔单抗治疗风湿性疾病：临床及影像学疗效

Infliximab treatment for rheumatic disease: clinical and radiological efficacy.

作者信息

St Clair E W

机构信息

Department of Medicine, Division of Rheumatology, Duke University Medical Center, Durham, NC, USA.

出版信息

Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii67-9. doi: 10.1136/ard.61.suppl_2.ii67.

DOI:10.1136/ard.61.suppl_2.ii67
PMID:12379627
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1766724/
Abstract

Infliximab is a chimeric anti-tumour necrosis factor alpha (TNFalpha) monoclonal antibody with high affinity and binding specificity for human TNFalpha. Results from several well designed, controlled clinical trials show repeated infusions of infliximab with concomitant methotrexate (MTX) treatment can reduce the signs and symptoms of rheumatoid arthritis (RA). This combination of infliximab and MTX also slows the radiological progression of joint damage, decreases functional disability, and improves qualify of life. These remarkably positive results have led to the investigation of infliximab treatment for other rheumatic diseases. Recently, controlled studies have shown treatment with infliximab can benefit patients with active spondyloarthropathy. TNFalpha has fast become an important therapeutic target in rheumatology.

摘要

英夫利昔单抗是一种嵌合型抗肿瘤坏死因子α（TNFα）单克隆抗体，对人TNFα具有高亲和力和结合特异性。多项设计良好的对照临床试验结果表明，重复输注英夫利昔单抗并同时使用甲氨蝶呤（MTX）治疗可减轻类风湿关节炎（RA）的体征和症状。英夫利昔单抗与MTX的这种联合治疗还可减缓关节损伤的放射学进展，降低功能残疾，并改善生活质量。这些显著的积极结果促使人们对英夫利昔单抗治疗其他风湿性疾病进行研究。最近，对照研究表明，英夫利昔单抗治疗可使活动性脊柱关节炎患者受益。TNFα已迅速成为风湿病学中的一个重要治疗靶点。